Osteoporosis in Men

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition

Volumn , Issue , 2013, Pages 508-513

  Orwoll, Eric S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aging; Fracture epidemiology; Hypogonadism; Idiopathic osteoporosis; Men; Osteoporosis; Parathyroid hormone (PTH) therapy; Skeletal development

Indexed keywords

EID: 85013700143     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118453926.ch62     Document Type: Chapter

References (42)

1. Seeman E. 2001. Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 86 (10): 4576-84.
2. Marcus R, Feldman D, Kelsey JL. 2001. Osteoporosis, 2nd Ed. San Diego: Academic Press.
3. Seeman E. 2002. Pathogenesis of bone fragility in women and men. Lancet 359 (9320): 1841-50.
4. Donaldson LJ, Cook A, Thomson RG. 1990. Incidence of fractures in a geographically defined population. J Epi Comm Health 44: 241-5.
5. Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, Banzer D, Benevolenskaya LI, Bhalla A, Armas JB, Cannata JB, Cooper C, Delmas PD, Dequeker J, Dilsen G, Falch JA, Felsch B, Felsenberg D, Finn JD, Gennari C, Hoszowski K, Jajic I, Janott J, Johnell O, Kanis JA, Kragl G, Vaz AL, Lorenc R, Lyritis G, Marchand F, Masaryk P, Matthis C, Miazgowski T, Naves-Diaz M, Pols HAP, Poor G, Rapido A, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, O ' Neill TW. 2002. Incidence of limb fracture across Europe: Results from the European prospective osteoporosis study (EPOS). Osteoporos Int 13: 565-71.
6. Group EPOSE. 2002. Incidence of vertebral fracture in Europe: Results from the European prospective osteoporosis study (EPOS). J Bone Miner Res 17 (4): 716-24.
7. Amin S, Felson DT. 2001. Osteoporosis in men. Rheum Dis Clin North Am 27 (1): 19-47.
8. Schwartz AV, Kelsey JL, Maggi S, Tuttleman M, Ho SC, Jonsson PV, Poor G, Sisson de Castro JA, Xu L, Matkin CC, Nelson LM, Heyse SP. 1999. International variation in the incidence of hip fractures: Cross-national project on osteoporosis for the world health organization program for research on aging. Osteoporos Int 9: 242-53.
9. Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA. 2011. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22 (5): 1277-88.
10. Leslie WD, O ' Donnell S, Jean S, Lagace C, Walsh P, Bancej C, Morin S, Hanley DA, Papaioannou A. 2009. Trends in hip fracture rates in Canada. JAMA 302 (8): 883-9.
11. Xia WB, He SL, Xu L, Liu AM, Jiang Y, Li M, Wang O, Xing XP, Sun Y, Cummings SR. 2011. Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 27 (1): 125-9.
12. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. 1996. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 144 (3): 258-61.
13. Chan BKS, Marshall LM, Lambert LC, Cauley JA, Ensrud KE, Orwoll ES, Cummings SR. 2005. The risk of nonvertebral and hip fracture and prevalent falls in older men: The MrOS Study. J Bone Miner Res 20 (Suppl 1): S385.
14. Vanderschueren D, Boonen S, Bouillon R. 2000. Osteoporosis and osteoportic fractures in men: A clinical perspective. Baillieres Best Pract Res Clin Endocrinol Metab 14 (2): 299-315.
15. Khosla S, Melton J 3rd. 2002. Estrogen and the male skeleton. J Clin Endocrinol Metab 87 (4): 1443-50.
16. Vanderscheuren D, Boonen S, Bouillon R. 1998. Action of androgens versus estrogens in male skeletal homeostasis. Bone 23: 391-4.
17. Orwoll ES. 2003. Men, bone and estrogen: Unresolved issues. Osteoporos Int 14 (2): 93-8.
18. Leder BZ, Le Blanc KM, Schoenfeld DA, Eastell R, Finkelstein J. 2003. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88 (1): 204-10.
19. Falahati-Nini A, Riggs BL, Atkinson EJ, O ' Fallon WM, Eastell R, Khosla S. 2000. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106: 1553-60.
20. Orwoll ES. 2001. Androgens: Basic biology and clinical implication. Calcif Tissue Int 69: 185-8.
21. Mellström D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, Odén A, Johansson H, Orwoll ES, Labrie F, Karlsson MK. 2008. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23: 1552-60.
22. LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, Hoffman AR, Laughlin G, Ohlsson C, Orwoll ES. 2009. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab 94 (9): 3337-46.
23. Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, Orwoll ES. 2006. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91 (10): 3908-15.
24. Nguyen ND, Pongchaiyakul C, Center JR, Eisman JA, Nguyen TV. 2005. Identification of high-risk individuals for hip fracture: A 14-year prospective study. J Bone Miner Res 20 (11): 1921-8.
25. Binkley NC, Schmeer P, Wasnich RD, Lenchik L. 2002. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-caucasians? J Clin Densitom 5 (Suppl): 19-27.
26. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ, 3rd, Bauer DC, Ensrud KE. 2007. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 298 (6): 629-37.
27. Dawson-Hughes B, Tosteson ANA, Melton LJ, Baim S, Favus MJ, Khosla S, Lindsay RL. 2008. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19 (4): 449-58.
28. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O ' Neill T, Pols H, Reeve J, Silman A, Tenenhouse A. 2005. Predictive value of BMD for hip and other fractures. J Bone Miner Res 20 (7): 1185-94.
29. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES. 2006. BMD and risk of hip and nonvertebral fractures in older men: A prospective study and comparison with older women. J Bone Miner Res 21 (10): 1550-56.
30. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. 2005. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2): 154-64.
31. Nielsen M, Brixen K, Walter S, Andersen J, Eskildsen P, Abrahamsen. 2007. Fracture risk is increased in danish men with prostate cancer: A nation-wide register study. Abstracts of the 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, HI.
32. Ross CA, Taylor CL, Yaktine AL, Del Valle HB (eds.); Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Institute of Medicine. 2011. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press.
33. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. 2000. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 (9): 604-10.
34. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. 2003. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18 (1): 9-17.
35. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. 2007. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357: nihpa40967.
36. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA. 1997. Intermittent etidronate therapy to prevent corticosteroidinduced osteoporosis. N Engl J Med 337 (6): 382-7.
37. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP. 2000. Efficacy and safety of daily residronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res 15: 1006-13.
38. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C. 2009. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361 (8): 745-55.
39. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. 2005. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90 (3): 1502-10.
40. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. 2004. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89 (2): 503-10.
41. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. 2000. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85 (8): 2670-7.
42. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS. 2012. Osteoporosis in men: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97 (6): 1802-22.